Cellebrite DI (CLBT) | Stock Overview & Key Data
Cellebrite DI Performance Comparison
Stock Range
Today's Range
Low: $15.75
High: $16.20
on August 22, 2025
52 Week Range
Low: $13.10
High: $26.30
on August 11, 2025
on February 6, 2025
All-Time High: $26.30 on February 3, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.9B
EPS
-0.72
P/E Ratio (TTM)
69.09
Forward P/E
39.88
P/B Ratio
9.55
PEG Ratio
39.88
Div. Yield
N/A
ROE
-81.98%
Beta
1.267
Debt to Equity
5.47
Financial Highlights
Profitability
Gross Margin
84.39%
Operating Margin
14.58%
Profit Margin
-34.56%
Returns and Earnings
Return on Assets (TTM)
5.95%
Return on Equity (TTM)
-81.98%
EBITDA
$74.5M
Net Income (TTM)
$-150.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.86
Quarterly Revenue Growth (YoY)
18.30%
Quarterly Earnings Growth (YoY)
18.35%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Cellebrite DI CLBT | 3.90B Mid-cap | 3.27% | 12.97% | -3.59% | -14.99% | -25.62% | -6.01% | 235.83% | 66.87% |
| Microsoft MSFT | 3.82T Mega-cap | -2.49% | 0.39% | 11.51% | 25.55% | 21.18% | 21.70% | 89.20% | 121.58% |
| Oracle ORCL | 654.91B Mega-cap | -4.80% | -0.73% | 50.26% | 39.07% | 42.37% | 69.82% | 216.64% | 308.38% |
| Amdocs DOX | 9.53B Mid-cap | 1.04% | -1.35% | -3.66% | -0.05% | 4.88% | 3.32% | 2.25% | 45.11% |
| Klaviyo KVYO | 9.83B Mid-cap | 4.26% | 0.06% | -2.76% | -21.17% | -21.30% | 0.28% | -1.86% | -1.86% |
| Shift4 Payments FOUR | 7.96B Mid-cap | 0.31% | -14.66% | 4.10% | -6.04% | -15.89% | 12.33% | 98.50% | 77.50% |
Ownership & Short Interest
Insider Ownership
44.61%
Institutional Ownership
49.56%
Shares Short
4M
Short Ratio
2.40
Short % of Shares Outstanding
3.14%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Cellebrite DI Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Cellebrite DI would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CLBT's 52-week high and low?
- In the last 52 weeks, Cellebrite DI reached a high of $26.30 (on February 6, 2025) and a low of $13.10 (on August 11, 2025).
- What is the market cap and P/E ratio for CLBT?
- Curious about Cellebrite DI's size and valuation? Its market capitalization stands at 3.90B. When it comes to valuation, the P/E ratio (trailing twelve months) is 69.09, and the forward P/E (looking ahead) is 39.88.
- Does CLBT pay dividends? If so, what's the yield?
- As for dividends, Cellebrite DI isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cellebrite DI's main competitors or similar companies to consider before investing?
When looking at Cellebrite DI, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Microsoft
MSFT3.82T Technology Software - Infrastructure 21.70% 89.20% Oracle
ORCL654.91B Technology Software - Infrastructure 69.82% 216.64% Amdocs
DOX9.53B Technology Software - Infrastructure 3.32% 2.25% Klaviyo
KVYO9.83B Technology Software - Infrastructure 0.28% -1.86% Shift4 Payments
FOUR7.96B Technology Software - Infrastructure 12.33% 98.50% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cellebrite DI Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Cellebrite DI's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -81.98%, the Debt to Equity ratio from the most recent quarter is 5.47, and its Gross Profit Margin stands at 84.39%.
- What is the recent revenue and earnings growth for CLBT?
- Looking at Cellebrite DI's growth, its revenue over the trailing twelve months (TTM) was $437M. Compared to the same quarter last year (YoY), quarterly revenue grew by 18.30%, and quarterly earnings saw a YoY growth of 18.35%.
- How much of CLBT stock is held by insiders and institutions?
- Wondering who owns Cellebrite DI stock? Company insiders (like executives and directors) hold about 44.61% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 49.56%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.